Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02212262 · ClinicalTrials.gov registry record
Role of Osteocytes in Myeloma Bone Disease
A clinical trial of Multiple Myeloma, sponsored by Attaya Suvannasankha.
- Completed
- Registry status
- 67
- Enrollment target
- 2
- Study locations
NCT02212262: Completed study of Multiple Myeloma, sponsored by Attaya Suvannasankha.
NCT02212262 is a study of Multiple Myeloma that has completed, run by Attaya Suvannasankha. The registered enrollment target is 67 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02212262, a study of Multiple Myeloma, has completed, sponsored by Attaya Suvannasankha.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
- 2
- Study locations
Study Summary
Progress in the treatment of myeloma and myeloma bone disease has substantially increased overall survival, but relapse is inevitable and better treatment is needed. The bone microenvironment is tremendously complex, so that targeting single interactions between tumor and bone is unlikely to be effective. Treatments need to block centrally important, multifunctional pathways. The investigators data point to a central role of the osteocyte to induce heparanase, a multifunctional mediator of myeloma bone disease. Increased heparanase due to FGF23 may make systemic inhibitors of heparanase less effective in bone than elsewhere. FGF23 neutralizing antibodies have been developed for non-cancer conditions of FGF23 excess, such as chronic kidney disease (Shimada \& Fukamoto, 2012), and could be used in MM alone or in combination with heparanase inhibitors. Complete neutralization of FGF23 has adverse effects, but neutralization of FGF23 excess may be practical, or in the future, suppression of excess FGF23 biosynthesis by osteocytes. The investigators hope to determine serum FGF23 and heparanase, Dkk1 and plasma klotho levels in patients with newly diagnosed and relapsed myeloma compared to healthy controls with this exploratory study.
Conditions Studied
Study Locations (2)
Indiana
- Indiana University Simon Cancer Center - Indianapolis
- VA Roudebush Medical Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2014-10-07 |
| Est. Completion | 2022-02-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02212262
The ClinicalTrials.gov registry entry for NCT02212262 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (88% lower). The listed sponsor is Attaya Suvannasankha, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT02212262 reports 2 study locations spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT02212262 about?
NCT02212262 is a clinical study titled "Role of Osteocytes in Myeloma Bone Disease". Progress in the treatment of myeloma and myeloma bone disease has substantially increased overall survival, but relapse is inevitable and better treatment is needed. The bone microenvironment is tremendously complex, so that targeting single interactions between tumor and bone is unlikely to be effe...
What is the current status of trial NCT02212262?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2014-10-07. Estimated completion is 2022-02-05.
What conditions does trial NCT02212262 study?
This clinical trial studies the following conditions: Multiple Myeloma.
Who is sponsoring clinical trial NCT02212262?
This trial is sponsored by Attaya Suvannasankha, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02212262 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.